Background: Anxiety and depression are highly prevalent conditions in cervical dystonia and considered intrinsic to the disease mechanism. Psychiatric symptoms do not appear to be influenced by botulinum toxin therapy. Studies focusing on changes in mood disorder during the course of the disease are limited in this chronic, lifelong disorder. Objective: To assess the longitudinal prevalence of mood disorder, pain, and quality of life in patients with cervical dystonia attending a botulinum toxin clinic. Methods: Patients involved in phase I of our study were invited to be involved in reassessment using the Beck Depression Inventory, Second Revision; Beck Anxiety Index; Cervical Dystonia Impact Profile-58 (CDIP-58); and the Toronto Western Spasmodic Torticollis Rating Scale-2 Pain Scale (TWSTRS2-Pain). Results: A total of 53 participants took part after a mean study interval duration of 24 months. There were no significant differences between the 2 study time points in the prevalence of anxiety (P = 0.2919) and depressive symptoms (P = 0.5). Self-reported quality of life by CDIP-58 (P = 0.96) and pain by TWSTRS2-Pain (P = 0.9321) were unchanged. Men and women with significant symptoms of mood disorder had an earlier age of onset of cervical dystonia (P = 0.008). Conclusion: Anxiety and depressive symptoms persist in cervical dystonia, seem to be unrelated to pain severity, and need to be specifically targeted to improve quality of life. The relationship between mood disorder and age of onset suggest that mood disorder may be part of the disease pathophysiology.
Background: Anxiety and depression are highly prevalent conditions in cervical dystonia and considered intrinsic to the disease mechanism. Psychiatric symptoms do not appear to be influenced by botulinum toxin therapy. Studies focusing on changes in mood disorder during the course of the disease are limited in this chronic, lifelong disorder. Objective: To assess the longitudinal prevalence of mood disorder, pain, and quality of life in patients with cervical dystonia attending a botulinum toxin clinic. Methods: Patients involved in phase I of our study were invited to be involved in reassessment using the Beck Depression Inventory, Second Revision; Beck Anxiety Index; Cervical Dystonia Impact Profile-58 (CDIP-58); and the Toronto Western Spasmodic Torticollis Rating Scale-2 Pain Scale (TWSTRS2-Pain). Results: A total of 53 participants took part after a mean study interval duration of 24 months. There were no significant differences between the 2 study time points in the prevalence of anxiety (P = 0.2919) and depressive symptoms (P = 0.5). Self-reported quality of life by CDIP-58 (P = 0.96) and pain by TWSTRS2-Pain (P = 0.9321) were unchanged. Men and women with significant symptoms of mood disorder had an earlier age of onset of cervical dystonia (P = 0.008). Conclusion: Anxiety and depressive symptoms persist in cervical dystonia, seem to be unrelated to pain severity, and need to be specifically targeted to improve quality of life. The relationship between mood disorder and age of onset suggest that mood disorder may be part of the disease pathophysiology.
Authors: Alberto Albanese; Francesca Del Sorbo; Cynthia Comella; H A Jinnah; Jonathan W Mink; Bart Post; Marie Vidailhet; Jens Volkmann; Thomas T Warner; Albert F G Leentjens; Pablo Martinez-Martin; Glenn T Stebbins; Christopher G Goetz; Anette Schrag Journal: Mov Disord Date: 2013-06-15 Impact factor: 10.338
Authors: Mark Hallett; Alberto Albanese; Dirk Dressler; Karen R Segal; David M Simpson; Daniel Truong; Joseph Jankovic Journal: Toxicon Date: 2013-02-04 Impact factor: 3.033
Authors: Niccolò E Mencacci; Regina Reynolds; Sonia Garcia Ruiz; Jana Vandrovcova; Paola Forabosco; Alvaro Sánchez-Ferrer; Viola Volpato; Michael E Weale; Kailash P Bhatia; Caleb Webber; John Hardy; Juan A Botía; Mina Ryten Journal: Brain Date: 2020-09-01 Impact factor: 13.501
Authors: Michael Hutchinson; Tadashi Isa; Anna Molloy; Okka Kimmich; Laura Williams; Fiona Molloy; Helena Moore; Daniel G Healy; Tim Lynch; Cathal Walsh; John Butler; Richard B Reilly; Richard Walsh; Sean O'Riordan Journal: Front Neurol Date: 2014-04-28 Impact factor: 4.003